TOMI Environmental targets $12 million 2026 revenue, expects profitable Q4
Bitget2026/10/08 12:33TOMI Environmental Solutions forecast full-year 2026 revenue of USD 12 million, contingent on execution. Management expected fourth-quarter profitability, with continued profitability projected into the foreseeable future. Outlook followed preliminary Q3 revenue of USD 2.5 million, up 27% year over year, up 13% sequentially. Recognized year-to-date revenue combined with open order book totaled USD 9 million as of Sept. 30. Open order book was USD 2.5 million, with USD 1.7 million booked for Q4. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TOMI Environmental Solutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080830PRIMZONEFULLFEED9842138) on October 08, 2026, and is solely responsible for the information contained therein.
- TOMI Environmental Solutions forecast full-year 2026 revenue of USD 12 million, contingent on execution.
- Management expected fourth-quarter profitability, with continued profitability projected into the foreseeable future.
- Outlook followed preliminary Q3 revenue of USD 2.5 million, up 27% year over year, up 13% sequentially.
- Recognized year-to-date revenue combined with open order book totaled USD 9 million as of Sept. 30.
- Open order book was USD 2.5 million, with USD 1.7 million booked for Q4.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
